Search | Clinical Trials Finder

Conditions: Chronic Hepatitis B
Interventions: ABI-H0731, SOC NUC, Placebo Oral Tablet; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 17
States / cities: Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more

Conditions: HIV Infections
Interventions: Truvada (tenofovir/emtricitabine), Kaletra (lopinavir/ritonavir); Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir; Drug
Lead sponsor: Margaret A. Fischl, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 75
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more

Conditions: HIV Infection
Interventions: 3MV, PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®)); Behavioral · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 22 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: Hiv, Hormone Therapy
Interventions: Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Emtricitabine Tenofovir Alafenamide 200/25 mg; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: [11c] LAAM, Ritonavir, Efavirenz; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Hepatitis B
Interventions: Tenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV), TDF placebo, FTC/TDF placebo, ETV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 5 more

Conditions: HIV Infections
Interventions: Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Miami, Florida

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Los Angeles, California • Sacramento, California • Ft. Pierce, Florida + 16 more

Conditions: HIV
Interventions: Truvada qd, Maraviroc 300 qd; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hepatitis B Virus (HBV)
Interventions: Tenofovir disoproxil fumarate (TDF), Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Oakland, California • Indianapolis, Indiana • Seattle, Washington

Conditions: Hepatitis B, Chronic
Interventions: JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA); Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more

Conditions: HIV Infections
Interventions: Daily dosing, Time-driven dosing, Event-driven dosing; Drug
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg, Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs), Etravirine (ETR) 200 mg, Tenofovir disoproxil fumarate (TDF) 300 mg; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 10
States / cities: Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: NNRTI, FTC/TDF, Stribild; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 39
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more

Conditions: HIV-1
Interventions: Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 84
States / cities: Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Efavirenz, Stavudine, Zidovudine, Lamivudine, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 775 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more

Conditions: HIV Infections
Interventions: Kaletra + Isentress, Atripla; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 3 more

Conditions: HIV Infections, Hepatitis C
Interventions: Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: HIV Infections
Interventions: FDA Approved Antiretroviral Therapy (see list below); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more

Conditions: HIV
Interventions: Stribild, Genvoya; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Human Immunodeficiency Virus Infection
Interventions: lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more

Search by objective public record fields.

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

LAAM-HAART PET Imaging

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Clinical Trial of CNS-targeted HAART (CIT2)

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)